- Conditions
- Diabetes Mellitus, Type 2, Food Supply, Poverty, Minority Health, Obesity
- Interventions
- Fresh organic vegetables
- Dietary Supplement
- Lead sponsor
- Sansum Diabetes Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 303 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Santa Barbara, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 529–552
of 29,129
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Major Depressive Disorder
- Interventions
- SHX-001 Active low dose, Placebo, SHX-001 Active High dose
- Drug
- Lead sponsor
- Shenox Pharmaceuticals, LLC
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 3
- States / cities
- Gaithersburg, Maryland • Boston, Massachusetts • Dayton, Ohio
- Conditions
- Carcinoma, Renal Cell
- Interventions
- Sorafenib (Nexavar, BAY43-9006), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 903 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2010
- U.S. locations
- 31
- States / cities
- Tucson, Arizona • Los Angeles, California • Sacramento, California + 27 more
- Conditions
- Metastatic Melanoma
- Interventions
- CD24Fc, Ipilimumab, Nivolumab
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Hypertension, Pulmonary
- Interventions
- Selexipag, Placebo, Standard of Care (SOC): Endothelin receptor antagonist, SOC: Phosphodiesterase type 5 (PDE-5) inhibitor, SOC: Soluble guanylate cyclase stimulator
- Drug
- Lead sponsor
- Actelion
- Industry
- Eligibility
- 2 Years to 17 Years
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
- Conditions
- Non-small Cell Lung Cancer (NSCLC), Stage IV NSCLC, Metastatic NSCLC
- Interventions
- Cabazitaxel-XRP6258 (3-week cycle), Cabazitaxel-XRP6258 (5-week cycle)
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 28 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2015
- U.S. locations
- 2
- States / cities
- Birmingham, Alabama • Atlanta, Georgia
- Conditions
- Bronchoscopy
- Interventions
- Remifentanil, Fentanyl, Midazolam, Ketamine
- Drug
- Lead sponsor
- Beth Israel Deaconess Medical Center
- Other
- Eligibility
- 19 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- Group 1 ELND005, Group 2 ELND005
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 50 Years to 95 Years
- Enrollment
- 296 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 40
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Encino, California + 35 more
- Conditions
- Ovarian Cancer
- Interventions
- olaparib, paclitaxel, carboplatin, Drug: carboplatin
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years to 125 Years · Female only
- Enrollment
- 162 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2026
- U.S. locations
- 8
- States / cities
- Stanford, California • West Hollywood, California • Orlando, Florida + 4 more
- Conditions
- Renal Impairment
- Interventions
- Emraclidine
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2023 – 2024
- U.S. locations
- 5
- States / cities
- Tustin, California • Miami, Florida • Orlando, Florida + 1 more
- Conditions
- Depression
- Interventions
- Duloxetine, Escitalopram, BMS-820836 Placebo, BMS-820836
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 976 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 48
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Chino, California + 41 more
- Conditions
- Lymphoma
- Interventions
- carmustine, cyclophosphamide, etoposide, pharmacological study, autologous hematopoietic stem cell transplantation, peripheral blood stem cell transplantation
- Drug · Other · Procedure
- Lead sponsor
- City of Hope Medical Center
- Other
- Eligibility
- 10 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2026
- U.S. locations
- 1
- States / cities
- Duarte, California
- Conditions
- Essential Tremor
- Interventions
- SAGE-217, Placebo
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017
- U.S. locations
- 26
- States / cities
- Anniston, Alabama • Little Rock, Arkansas • Rogers, Arkansas + 23 more
- Conditions
- Renal Transplant
- Interventions
- Arm 1 Everolimus/Reduced dose tacrolimus
- Drug
- Lead sponsor
- University of Toledo Health Science Campus
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2020
- U.S. locations
- 1
- States / cities
- Toledo, Ohio
- Conditions
- Relapsed Acute Lymphoblastic Leukemia, Allergy to PEG e.Coli Asparaginase, Allergy to Native e.Coli Asparaginase
- Interventions
- Erwinase, Vincristine, Dexamethasone, Doxorubicin, Cytarabine, Methotrexate, Triple Intrathecal Therapy, Dexrazoxane
- Drug
- Lead sponsor
- Therapeutic Advances in Childhood Leukemia Consortium
- Other
- Eligibility
- 1 Year to 21 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Type 1 Diabetes Mellitus
- Interventions
- LY3209590, Insulin Degludec
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 266 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2021
- U.S. locations
- 33
- States / cities
- Concord, California • Fresno, California • Ventura, California + 29 more
- Conditions
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
- Interventions
- Rituximab
- Drug
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 82 Years
- Enrollment
- 115 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- Cevostamab
- Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Ulcerative Colitis
- Interventions
- SHR0302, Placebo
- Drug
- Lead sponsor
- Reistone Biopharma Company Limited
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 3
- States / cities
- Lake Wales, Florida • Tampa, Florida • Oklahoma City, Oklahoma
- Conditions
- DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
- Interventions
- Dexamethasone, Laboratory Biomarker Analysis, Lenalidomide, Thalidomide
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 452 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2027
- U.S. locations
- 138
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 115 more
- Conditions
- Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic
- Interventions
- Sabatolimab, Azacitidine, Placebo
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years
- Enrollment
- 530 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 11
- States / cities
- Yuma, Arizona • Los Angeles, California • New Haven, Connecticut + 8 more
- Conditions
- Small Cell Lung Cancer
- Interventions
- Rovalpituzumab tesirine, Topotecan, Dexamethasone
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 444 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 31
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Little Rock, Arkansas + 28 more
- Conditions
- Pain
- Interventions
- Real acupuncture, Sham acupuncture, VGAIT, VGAIT control
- Other
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017
- U.S. locations
- 1
- States / cities
- Charlestown, Massachusetts
- Conditions
- NSCLC, Non Small Cell Lung Cancer, RCC, Renal Cell Cancer, Pancreatic Cancer, Urothelial Cancer, Head and Neck Cancer, DLBCL, Diffused Large B Cell Lymphoma, MSS, Microsatellite Stable Colon Cancer, TNBC, Triple Negative Breast Cancer, Melanoma, mCRPC, Metastatic Castration Resistant Prostate Cancer
- Interventions
- NIR178, PDR001
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 5
- States / cities
- Santa Monica, California • Tampa, Florida • Baltimore, Maryland + 2 more